Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Raymond Miao"'
Autor:
April W Armstrong, Ahong Huang, Li Wang, Raymond Miao, Miraj Y Patel, Abhijit Gadkari, Usha G Mallya, Jingdong Chao
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210517 (2019)
At the time of this study, prior to the introduction of biologics in the US, systemic therapies used for the treatment of moderate-to-severe atopic dermatitis included off-label immunosuppressants and corticosteroids. Immunosuppressant therapy is ass
Externí odkaz:
https://doaj.org/article/60530dbd20c94b2797e1c2c246099422
Autor:
Usha G. Mallya, Julie Héroux, Amy S. Paller, Abhijit Gadkari, Francis Vekeman, Mandeep Kaur, Elaine C. Siegfried, Raymond Miao, Paola Mina-Osorio
Publikováno v:
BMC Dermatology, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Dermatology
BMC Dermatology
Background An estimated 50% of children in the US are Medicaid-insured. Some of these patients have poor health literacy and limited access to medications and specialty care. These factors affect treatment utilization for pediatric patients with atop
Publikováno v:
BJU International. 121:871-879
OBJECTIVES To assess treatment patterns and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy or antiandrogen therapy. PATIENTS AND METHODS Patients initiating first-line antiandrogen
Autor:
Raymond Miao, Jennifer Sung, Wendy Y. Cheng, Marjolaine Gauthier-Loiselle, Francis Vekeman, Ravinder Dhawan, Mei Sheng Duh, William Oh
Publikováno v:
Clinical Genitourinary Cancer. 16:50-57
In metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequences are unknown. We assessed second-line taxane (TT) versus androgen receptor-targeted therapy (ART), after initial ART failure, in United States oncology community p
Publikováno v:
Advances in Therapy
Introduction Comparative data on the burden of atopic dermatitis (AD) in adults relative to the general population are limited. We performed a large-scale evaluation of the burden of disease among US adults with AD relative to matched non-AD controls
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 23:416-426
With the approval of several new treatments for metastatic castration-resistant prostate cancer (mCRPC), budgetary impact is a concern for health plan decision makers. Budget impact models (BIMs) are becoming a requirement in many countries as part o
Autor:
Raymond Miao, Usha G. Mallya, Francis Vekeman, Amy S. Paller, Mandeep Kaur, Julie Héroux, Elaine C. Siegfried, Paola Mina-Osorio, Abhijit Gadkari
Publikováno v:
Journal of the American Academy of Dermatology. 82(3)
Real-world evidence on treatment patterns of pediatric patients with atopic dermatitis (AD) is sparse.To assess current treatment patterns in pediatric AD patients.Retrospective observational analysis of commercial insurance and Medicaid administrati
Autor:
Jingdong Chao, Miraj Y. Patel, April W. Armstrong, Raymond Miao, Li Wang, Ahong Huang, Abhijit Gadkari, Usha G. Mallya
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210517 (2019)
PLoS ONE
PLoS ONE
At the time of this study, prior to the introduction of biologics in the US, systemic therapies used for the treatment of moderate-to-severe atopic dermatitis included off-label immunosuppressants and corticosteroids. Immunosuppressant therapy is ass
Autor:
Usha Sambamoorthi, Sandipan Bhattacharjee, Amit D. Raval, Steve Zhou, Wenhui Wei, Raymond Miao
Publikováno v:
Population Health Management. 18:256-264
This study retrospectively assessed rates and risk factors for all-cause hospital readmission among elderly Medicare beneficiaries with type 2 diabetes mellitus (T2DM) aged ≥65 years. Associations between 30-day readmission and patients' demographi
Autor:
Marjolaine Gauthier-Loiselle, Wendy Y. Cheng, Ravinder Dhawan, Francis Vekeman, Jennifer Sung, Raymond Miao, Mei Sheng Duh, William Oh
Publikováno v:
Medical Oncology (Northwood, London, England)
It is unclear how treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC) affects real-world patient outcomes. We assessed treatment sequences, patient characteristics and overall survival (OS) in post-docetaxel mCRPC patient